See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot3,994▼ 0.75%WTI103.27▲ 3.82%
London Exchange · UK · Updated after 23 Oct 2026 close

Viking Therapeutics, Inc.

0VQA · London Exchange · prices in USD
USD 24.50▼ -1.39 (5.37%)
Research reportHistorical data

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, that develops treatments for metabolic and endocrine disorders. Its work centres on drug candidates for obesity and related conditions, including an injectable and an oral medicine that act on gut hormone receptors, and an oral compound aimed at a liver disease linked to fat accumulation. The company carries out research and clinical testing rather than marketing approved products, and its activities serve patients and physicians in the metabolic disease field.

The shares are listed on the London Exchange in UK under the code 0VQA, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

24/ 100
Market X-Ray · price-based
Weak price profile
Ranks #3320 of 3787 on the London Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
21/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-24.8%
From 52-week high-40.8%
MomentumWeak
10/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-31.9%
6-month return-26.5%
Stability (higher is calmer)Weak
23/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)65.2%
Worst drawdown, 1 year (smaller is calmer)-40.8%
LiquidityFair
51/100
Moderate trading activity.
See the numbers →
Avg daily value traded0.82M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
24.46 – 45.90
Price is 0% of the way up
Returns
−31.9% 3m · – 1y
Price returns, dividends not included
RSI (14)
35
Neutral zone

Price chart

52-wk range 24.46 – 45.90 Daily closes, split-adjusted

Signals

50-day average31.29
200-day average32.57
Golden/death cross (60d)Death, 13 days ago
New 52-week highNo
Bullish RSI divergenceYes
Average daily range (ATR)1.92

Technical summary

Daily
Strongly bearish
3 bullish · 1 neutral · 11 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
0 bullish · 0 neutral · 1 bearish
Moving averages (daily)
SMA 1026.21Bearish
EMA 1026.40Bearish
SMA 2028.25Bearish
EMA 2027.92Bearish
SMA 5031.29Bearish
EMA 5030.40Bearish
SMA 10032.98Bearish
EMA 10031.80Bearish
SMA 20032.57Bearish
EMA 200–n/a
Oscillators (daily)
RSI (14)35.00Neutral
MACD (12, 26)-1.90Bearish
Momentum (12)-13.93Bearish
Stochastic %K (14)0.75Bullish
Williams %R (14)-99.25Bullish
CCI (20)-103.3Bullish
Pivot points (classic, last session)
S3
21.70
S2
23.08
S1
23.79
Pivot
25.17
R1
25.88
R2
27.26
R3
27.97
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in USD. Educational only, not financial advice.